THALIDOMIDE CELGENE Trademark

Trademark Overview

On Friday, January 20, 2017, a trademark application was filed for THALIDOMIDE CELGENE with the United States Patent and Trademark Office. The USPTO has given the THALIDOMIDE CELGENE trademark a serial number of 87308448. The federal status of this trademark filing is CANCELLED - SECTION 8 as of Friday, March 15, 2024. This trademark is owned by Celgene Corporation. The THALIDOMIDE CELGENE trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations used to treat cancers and immune related diseases
thalidomide celgene

General Information

Serial Number87308448
Word MarkTHALIDOMIDE CELGENE
Filing DateFriday, January 20, 2017
Status710 - CANCELLED - SECTION 8
Status DateFriday, March 15, 2024
Registration Number5276044
Registration DateTuesday, August 29, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 13, 2017

Trademark Statements

Goods and Servicespharmaceutical preparations used to treat cancers and immune related diseases
Disclaimer with Predetermined Text"THALIDOMIDE"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code2 - Sec. 8 - Entire Registration
Class Status DateFriday, March 15, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCelgene Corporation
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901
Party NameCelgene Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSummit, NJ 07901

Trademark Events

Event DateEvent Description
Friday, March 15, 2024CANCELLED SEC. 8 (6-YR)
Friday, December 9, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, December 9, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, December 9, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, December 9, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, December 9, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, December 9, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 29, 2022COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, August 29, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, June 13, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 13, 2017PUBLISHED FOR OPPOSITION
Wednesday, May 24, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, May 5, 2017LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, April 27, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, April 27, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, April 27, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 19, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 18, 2017NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 18, 2017NON-FINAL ACTION E-MAILED
Tuesday, April 18, 2017NON-FINAL ACTION WRITTEN
Friday, April 14, 2017ASSIGNED TO EXAMINER
Wednesday, March 8, 2017PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Thursday, March 2, 2017ASSIGNED TO LIE
Thursday, February 16, 2017TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, February 1, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 1, 2017NEW APPLICATION ENTERED

Related Keywords

celgene thalidomide immune related diseases cancers treat preparations used pharmaceutical